Tag: ADC therapy for HPV-related cancer

Home / ADC therapy for HPV-related cancer

Categories

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cer...
adc-therapy-for-hpv-related-cancer

Scan the code